Caltrate Bone Health Tablets

3775

Description

 

Caltrate Bone Health Tablets Indications

Caltrate Bone Health Tablets is primarily indicated in conditions like Hypocalcaemia of hypoparathyroidism, Hypoparathyroidism, Hypophosphataemia, Osteomalacia, Osteoporosis, Prevention of vitamin d deficiency, Renal osteodystrophy, Simple vitamin d deficiency, Vitamin D deficiency, Vitamin D deficiency rickets, and can also be given in adjunctive therapy as an alternative drug of choice in Malabsorption, Post gastrectomy vit B-12 deficiency, Renal diseases.

Contraindication

Caltrate Bone Health Tablets is contraindicated in conditions like Hypercalcaemia.

Side Effects

The severe or irreversible adverse effects of Caltrate Bone Health Tablets, which give rise to further complications include Cardiac arrhythmias, Cardiac arrhythmias, Paralytic ileus, Thirst, Dehydration, Polyuria, Nocturia, Abdominal pain, Overt psychosis, Metastatic calcification, Hyperphosphatemia, Hypervitaminosis D.Caltrate Bone Health Tablets produces potentially life-threatening effects which include Cardiac arrhythmias, Renal failure. which are responsible for the discontinuation of Caltrate Bone Health Tablets therapy.The symptomatic adverse reactions produced by Caltrate Bone Health Tablets are more or less tolerable and if they become severe, they can be treated symptomatically, these include Weakness, Headache, Nausea, Vomiting, Anorexia, Apathy, Somnolence, Weakness.

Warnings

Evaluate Vitamin D administration in fortified food, diet and drugs. It may be necessary to limit dietary Vitamin D during treatment. If products of Vitamin D contain tartrazine may cause allergic reaction (including bronchial asthma) in susceptible individuals, Specially patients with aspirin hypersensitivity. Take care to ensure correct dose infants, monitor plasma calcium concentration in patient receiving high dose and in renal impairment.

 

Reviews

There are no reviews yet.

Be the first to review “Caltrate Bone Health Tablets”

Your email address will not be published. Required fields are marked *